BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37150235)

  • 1. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
    Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
    Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
    Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
    Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
    Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
    Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
    Yuan X; Yuan H; Zhang N; Liu T; Xu D
    Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classifying Melanoma by TERT Promoter Mutational Status.
    Shaughnessy M; Njauw CN; Artomov M; Tsao H
    J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible association of the TERT promoter polymorphisms rs2735940, rs7712562 and rs2853669 with diabetes mellitus in obese elderly Polish population: results from the national PolSenior study.
    Gutmajster E; Chudek J; Augusciak-Duma A; Szwed M; Szybalska A; Mossakowska M; Puzianowska-Kuznicka M; Wiecek A; Sieron AL
    J Appl Genet; 2018 Aug; 59(3):291-299. PubMed ID: 29938393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
    Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
    Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations in telomere biology.
    Heidenreich B; Kumar R
    Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation of the TERT promoter and its impact on human cancer.
    Lee DD; Komosa M; Nunes NM; Tabori U
    Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
    Giunco S; Padovan M; Angelini C; Cavallin F; Cerretti G; Morello M; Caccese M; Rizzo B; d'Avella D; Puppa AD; Chioffi F; De Bonis P; Zagonel V; De Rossi A; Lombardi G
    ESMO Open; 2023 Jun; 8(3):101570. PubMed ID: 37230028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations in clear cell renal cell carcinoma.
    Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
    Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
    J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.